Clinical Trials · NCT02278185

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
University of Colorado, Denver
Enrollment
19
Start date
Nov 2015
Locations
2 sites, United States
Primary endpoint
Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria
View Gonadorelin compound reference